Therapeutic Effect of Extracellular Vesicles Derived from HIF Prolyl Hydroxylase Domain Enzyme Inhibitor-Treated Cells on Renal Ischemia/Reperfusion Injury

Ding, Zhixia; Tang, Tao-Tao; Li, Zuo‐Lin; Cao, Jun; Lv, Lin‐Li; Wen, Yi; Wang, Bin; Liu, Bi‐Cheng

doi:10.1159/000522584

Cited by 6 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He mainly focused on the association of EVs with kidney-related diseases (AKI, CKD, renal inflammation and fibrosis, diabetic nephropathy, etc.). Moreover, he and his colleagues (Lv Lin-li, top 2; Wang Bin, top 3; Tang Tao-tao, top 10; Li Zuo-lin, top 9) also contributed to the correlation between EV and kidney-related disease research ( Lv et al, 2018a ; Tang et al, 2019a ; Wang et al, 2019a ; Tang et al, 2019b ; Lv et al, 2019 ; Tang and Liu, 2019 ; Tang et al, 2020a ; Tang et al, 2020c ; Wang et al, 2020 ; Cao et al, 2021a ; Feng et al, 2021a ; Feng et al, 2021b ; Tang et al, 2021 ; Ding et al, 2022 ; Tang et al, 2022 ). Interestingly, these researchers not only had the biggest collaboration network and active teamwork in this field but also the longest period in publication and the highest number of impact measures.…”

Section: Discussionmentioning

confidence: 99%

Bibliometric analysis of scientific papers on extracellular vesicles in kidney disease published between 1999 and 2022

Hun

Wen²,

Han³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: In recent years, there has been an increasing interest in using extracellular vesicles (EVs) as potential therapeutic agents or natural drug delivery systems in kidney-related diseases. However, a detailed and targeted report on the current condition of extracellular vesicle research in kidney-related diseases is lacking. Therefore, this prospective study was designed to investigate the use of bibliometric analysis to comprehensively overview the current state of research and frontier trends on extracellular vesicle research in kidney-related diseases using visualization tools.Methods: The Web of Science Core Collection (WoSCC) database was searched to identify publications related to extracellular vesicle research in kidney-related diseases since 1999. Citespace, Microsoft Excel 2019, VOSviewer software, the R Bibliometrix Package, and an online platform were used to analyze related research trends to stratify the publication data and collaborations.Results: From 1 January 1999 to 26 June 2022, a total of 1,122 EV-related articles and reviews were published, and 6,486 authors from 1,432 institutions in 63 countries or regions investigated the role of extracellular vesicles in kidney-related diseases. We found that the number of articles on extracellular vesicles in kidney-related diseases increased every year. Dozens of publications were from China and the United States. China had the most number of related publications, in which the Southeast University (China) was the most active institution in all EV-related fields. Liu Bi-cheng published the most papers on extracellular vesicles, while Clotilde Théry had the most number of co-citations. Most papers were published by The International Journal of Molecular Sciences, while Kidney International was the most co-cited journal for extracellular vesicles. We found that exosome-related keywords included exosome, exosm, expression, extracellular vesicle, microRNA, microvesicle, and liquid biopsy, while disease- and pathological-related keywords included biomarker, microRNA, apoptosis, mechanism, systemic lupus erythematosus, EGFR, acute kidney injury, and chronic kidney disease. Acute kidney disease (AKI), CKD, SLE, exosome, liquid biopsy, and extracellular vesicle were the hotspot in extracellular vesicle and kidney-related diseases research.Conclusion: The field of extracellular vesicles in kidney-related disease research is rapidly growing, and its domain is likely to expand in the next decade. The findings from this comprehensive analysis of extracellular vesicles in kidney-related disease research could help investigators to set new diagnostic, therapeutic, and prognostic ideas or methods in kidney-related diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric analysis of scientific papers on extracellular vesicles in kidney disease published between 1999 and 2022

Hun

Wen²,

Han³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Roxadustat protects against renal ischemia/reperfusion injury by inhibiting inflammation (Miao et al, 2021). And it also reported that extracellular vesicles (EVs) derived from HK2 or HEK293 cells after roxadustat treatment could alleviate renal tubular injury and inflammation, suggesting a novel therapeutic role of roxadustat/EVs in the treatment of AKI (Ding et al, 2022). The pretreatment of roxadustat improved the creatinine elevation and renal tubular injuries induced by ischemia.…”

Section: Roxadustat and Diabetic Nephropathymentioning

confidence: 96%

Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications

Fang

Ma²,

Zhang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a group of metabolic diseases caused by absolute or relative deficiency of insulin secretion and characterized by chronic hyperglycemia. Its complications affect almost every tissue of the body, usually leading to blindness, renal failure, amputation, etc. and in the final stage, it mostly develops into cardiac failure, which is the main reason why diabetes mellitus manifests itself as a high clinical lethality. The pathogenesis of diabetes mellitus and its complications involves various pathological processes including excessive production of mitochondrial reactive oxygen species (ROS) and metabolic imbalance. Hypoxia-inducible Factor (HIF) signaling pathway plays an important role in both of the above processes. Roxadustat is an activator of Hypoxia-inducible Factor-1α, which increases the transcriptional activity of Hypoxia-inducible Factor-1α by inhibiting hypoxia-inducible factor prolyl hydroxylase (HIF-PHD). Roxadustat showed regulatory effects on maintaining metabolic stability in the hypoxic state of the body by activating many downstream signaling pathways such as vascular endothelial growth factor (VEGF), glucose transporter protein-1 (GLUT1), lactate dehydrogenase (LDHA), etc. This review summarizes the current research findings of roxadustat on the diseases of cardiomyopathy, nephropathy, retinal damage and impaired wound healing, which also occur at different stages of diabetes and greatly contribute to the damage caused by diabetes to the organism. We attempts to uncover a more comprehensive picture of the therapeutic effects of roxadustat, and inform its expanding research about diabetic complications treatment.

show abstract

“…Supramolecular nanofibers containing arginine-glycine-aspartate (RGD) peptides improved the therapeutic effects of EVs in kidney repair [132], and platelet-rich plasma induced YAP nuclear expression to promote BMMSC proliferation, activating the AKT/Rab27 pathways to facilitate the paracrine secretion of MSC-derived exosomes for glycerol-induced AKI repair [133]. Additionally, hypoxia-induced activation of HIF-1α was also found to increase the loading of miR-21 in exosomes, thereby providing a therapeutic effect against septic/IRI-induced AKI [134].…”

Section: Exosome Modificationsmentioning

confidence: 99%

Exosomes Highlight Future Directions in the Treatment of Acute Kidney Injury

Zhang,

Wang,

Zhang

et al. 2023

IJMS

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a severe health problem associated with high morbidity and mortality rates. It currently lacks specific therapeutic strategies. This review focuses on the mechanisms underlying the actions of exosomes derived from different cell sources, including red blood cells, macrophages, monocytes, mesenchymal stem cells, and renal tubular cells, in AKI. We also investigate the effects of various exosome contents (such as miRNA, lncRNA, circRNA, mRNA, and proteins) in promoting renal tubular cell regeneration and angiogenesis, regulating autophagy, suppressing inflammatory responses and oxidative stress, and preventing fibrosis to facilitate AKI repair. Moreover, we highlight the interactions between macrophages and renal tubular cells through exosomes, which contribute to the progression of AKI. Additionally, exosomes and their contents show promise as potential biomarkers for diagnosing AKI. The engineering of exosomes has improved their clinical potential by enhancing isolation and enrichment, target delivery to injured renal tissues, and incorporating small molecular modifications for clinical use. However, further research is needed to better understand the specific mechanisms underlying exosome actions, their delivery pathways to renal tubular cells, and the application of multi-omics research in studying AKI.

show abstract

Therapeutic Effect of Extracellular Vesicles Derived from HIF Prolyl Hydroxylase Domain Enzyme Inhibitor-Treated Cells on Renal Ischemia/Reperfusion Injury

Cited by 6 publications

References 34 publications

Bibliometric analysis of scientific papers on extracellular vesicles in kidney disease published between 1999 and 2022

Bibliometric analysis of scientific papers on extracellular vesicles in kidney disease published between 1999 and 2022

Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications

Exosomes Highlight Future Directions in the Treatment of Acute Kidney Injury

Contact Info

Product

Resources

About